Bionovo Discovers New Estrogen Regulatory Elements For Breast Cancer And Osteoporosis Drugs

Bionovo Inc. (Nasdaq: BNVI) announced results on the role of estrogen
regulatory elements important in developing drugs notwithstanding knocker cancer and
osteoporosis. The data, which were presented at the Endocrine Society’s
90th Annual Convergence, showed that the inexperienced regulatory elements are important
for the differentiation of the estrogenic pharmacological activity exerted
by different compounds.

“Selective estrogen receptor modulators (SERMs) differ from estrogen in
how they regulate gene transcription and result in various
pharmacological profiles and clinical effects,” said Dr. Dale Leitman, from
the Department of Obstetrics, Gynecology and Reproductive Sciences at the
University of California, San Francisco. “This study identified gene
elements that are activated by SERMs but not by estrogens hardened in hormone
therapy. The identification of these elements, coupled with the
understanding of the differential regulation in various tissues, provides a
new tenets for the detection of estrogenic drugs with SERM-like
profiles.”

The study was conducted by investigators at The Center for Reproductive
Sciences in the Unit of Obstetrics, Gynecology and Reproductive
Sciences at the University of California, San Francisco in collaboration
with scientists at Bionovo.

“The discovery of these selective estrogen regulatory elements
strengthens our SERM discovery engine,” said Isaac Cohen, Bionovo’s
chairman and chief executive officer. “The interest of the new array of
specific regulatory elements is manifest in the pharmacological and
toxicological insights gained. We can at times into higher predictive value
and greater specificity from a very complex biological system. I take it
this puts Bionovo at the forefront of more in a flash developing future SERM
products which are far more specific.”

All over Bionovo’s SERM Platform

Bionovo is discovering and developing a new fathering of novel
eclectic estrogen modulators. The selectivity is based on receptor subtype
regulation, agonist, enemy truly, selective gene activation and
deterring and proper to recruitment of co-regulatory proteins. Selective
estrogen receptor modulators can be practical allowing for regarding many indications in women’s
health such as boob and uterine cancer, osteoporosis, menopausal
symptoms, vaginal atrophy, endometriosis, uterine fibroids and other
disorders. This podium provides Bionovo the molecular, pharmacological
and toxicological insights needed for drugs of the days.

About Bionovo

Bionovo is a pharmaceutical company focused on the discovery and
development of unhurt and effective treatments for women’s health and cancer,
which are markets with significant unmet needs and billions in imminent
annual revenue. The company applies its expertise in the biology of
menopause and cancer to work recent drugs derived from botanical sources
which have novel mechanisms of action. Based on the results of early and
mid-stage clinical trials, Bionovo believes they would rather discovered remodelled
classes of drug candidates within their well-heeled pipeline with the implicit to
be leaders in their markets. Bionovo is headquartered in Emeryville,
California and is traded on the NASDAQ Capital Peddle secondary to the symbol,
“BNVI”. For more information about Bionovo and its programs, visit
http://www.bionovo.com.

Forward Looking Statements

This releasing contains certain forward-looking statements relating to
the proprietorship of Bionovo, Inc. that can be identified by the use of
flip-looking terminology such as “believes,” “expects,” or similar
expressions. Such forward-looking statements involve known and unknown
risks and uncertainties, including uncertainties relating to product
development, efficacy and safety, regulatory actions or delays, the ability
to obtain or maintain patent or other proprietary intellectual property
custody, market acceptance, physician acceptance, third party
reimbursement, coming capital requirements, competition in normal and
other factors that may cause actual results to be substantially discrete from
those described herein as anticipated, believed, estimated or expected.
Sure of these risks and uncertainties are or will be described in
greater detail in our filings with the Securities and Exchange Commission,
which are accessible at http://www.sec.gov. Bionovo, Inc. is under no
obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a come to pass of new information,
future events or otherwise.

Bionovo Inc.
http://www.bionovo.com